PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Immunology Section, Department of Medicine.\', \'Internal Medicine Section B, Department of Medicine.\', \'Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.\', \'Intensive Care Unit, Department of Surgery, Dentistry, Maternity and Infant, University and Hospital Trust of Verona, Verona, Italy.\', \'Center for Advanced Studies and Technology (CAST), University of G. D\'Annunzio of Chieti-Pescara, Chieti, Italy.\', \'Department of Experimental Oncology, European Institute of Oncology (IEO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.\', \'Pederzoli Hospital, Peschiera sul Garda, Italy.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1172/JCI141772141772
?:doi
?:hasPublicationType
?:journal
  • The Journal of clinical investigation
is ?:pmid of
?:pmid
?:pmid
  • 32809969
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32809969>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32809969>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all